Advanced search
Publication Cover
Emerging Microbes & Infections Volume 4, 2015 - Issue 1
Submit an article Journal homepage
1,447
Views
32
CrossRef citations to date
0
Altmetric
Original Articles

Identification of new compounds with high activity against stationary phase Borrelia burgdorferi from the NCI compound collection

Jie FengDepartment of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD21205, USA
,
Wanliang ShiDepartment of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD21205, USA
,
Shuo ZhangDepartment of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD21205, USA
&
Ying ZhangDepartment of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD21205, USACorrespondence[email protected]
Pages 1-15 | Received 20 Mar 2015, Accepted 08 May 2015, Published online: 25 Jan 2019

  • Centers for Disease Control and Prevention.Lyme Disease. Atlanta: CDC, 2014. Available at: http://www.cdc.gov/lyme/(accessed(accessed 13 September 2014) .
  • Radolf JD, Caimano MJ, Stevenson B, Hu LT.Of ticks, mice and men: understanding the dual-host lifestyle of Lyme disease spirochaetes. Nat Rev Microbiol 2012;10: 87–99 .
  • Centers for Disease Control and Prevention.Post-treatment Lyme Disease Syndrome. Atlanta: CDC, 2014.Available at : http://www.cdc.gov/lyme/postLDS/index.html (accessed 13 September 2014).
  • Barthold SW, Hodzic E, Imai DM, Feng S, Yang X, Luft BJ.Ineffectiveness of tigecycline against persistent Borrelia burgdorferi. Antimicrob Agents Chemother 2010;54: 643–651.
  • Embers ME, Barthold SW, Borda JT et al.Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection. PLoS One 2012;7: e29914.
  • Hodzic E, Imai D, Feng S, Barthold SW.Resurgence of persisting non-cultivable Borrelia burgdorferi following antibiotic treatment in mice. PLoS One 2014;9: e86907.
  • Straubinger RK, Summers BA, Chang YF, Appel MJ.Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. J Clin Microbiol 1997;35: 111–116.
  • Brorson O, Brorson SH, Scythes J, MacAllister J, Wier A, Margulis L.Destruction of spirochete Borrelia burgdorferi round-body propagules (RBs) by the antibiotic tigecycline. Proc Natl Acad Sci USA 2009;106: 18656–18661.
  • Sapi E, Bastian SL, Mpoy CM et al.Characterization of biofilm formation by Borrelia burgdorferi in vitro. PLoS One 2012;7: e48277.
  • Diterich I, Rauter C, Kirschning CJ, Hartung T.Borrelia burgdorferi-induced tolerance as a model of persistence via immunosuppression. Infect Immun 2003;71: 3979–3987.
  • Sapi E, Kaur N, Anyanwu S et al.Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi. Infect Drug Resist 2011;4: 97–113.
  • Feng J, Wang T, Shi W et al.Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library. Emerg Microb Infect 2014;3: e49.
  • Feng J, Wang T, Zhang S, Shi W, Zhang Y.An optimized SYBR Green I/PI assay for rapid viability assessment and antibiotic susceptibility testing for Borrelia burgdorferi. PLoS One 2014;9: e111809.
  • Feng J, Auwaerter PG, Zhang Y.Drug combinations against Borrelia burgdorferi persisters in vitro: eradication achieved by using daptomycin, cefoperazone and doxycycline. PLoS One 2015;10: e0117207.
  • Developmental Therapeutics Program NCI/NIH.Open Repository Collection of Synthetics and Pure Natural Products. Shady Grove: DTP, 2014.Available at : http://dtp.nci.nih.gov/branches/dscb/repo_open.html (accessed 15 March 2015).
  • Shopov A, Williams SC, Verity PG.Improvements in image analysis and fluorescence microscopy to discriminate and enumerate bacteria and viruses in aquatic samples. Aquat Microb Ecol 2000;22:103–110.
  • Clinical and Laboratory Standards Institute.Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement. CLSI document M100-S17 2007; 27: 154–161. Wayne: CLSI, 2007.Available at : http://www.microbilab-bg.com/CLSI.pdf (accessed 11 January 2015).
  • Moody MR, Morris MJ, Young VM, Moye LA 3rd, Schimpff SC, Wiernik PH.Effect of two cancer chemotherapeutic agents on the antibacterial activity of three antimicrobial agents. Antimicrob Agents Chemother 1978;14: 737–742.
  • Developmental Therapeutics Program NCI/NIH.Mechanistic Set Information. Shady GDTP, 2015.Available at : http://dtp.nci.nih.gov/branches/dscb/mechanistic_explanation.html (accessed 11 January 2015).
  • Developmental Therapeutics Program NCI/NIH.Natural Products Set III. Shady Grove: DTP, 2015.Available at : http://dtp.nci.nih.gov/branches/dscb/natprod_explanation2.html (accessed 11 January 2015).
  • Dever LL, Jorgensen JH, Barbour AG.In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies. J Clin Microbiol 1992;30: 2692–2697.
  • Boerner J, Failing K, Wittenbrink MM.In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: influence of test conditions on minimal inhibitory concentration (MIC) values. Zentralbl Bakteriol 1995;283: 49–60.
  • Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA.Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer 1967;20: 333–353.
  • Zhu L, Cao X, Chen W, Zhang G, Sun D, Wang PG.Syntheses and biological activities of daunorubicin analogs with uncommon sugars. Bioorg Med Chem 2005;13: 6381–6387.
  • Mizuno NS, Zakis B, Decker RW.Binding of daunomycin to DNA and the inhibition of RNA and DNA synthesis. Cancer Res 1975;35: 1542–1546.
  • Jensen PB, Sorensen BS, Sehested M et al.Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. Biochem Pharmacol 1993;45: 2025–2035.
  • Pommier Y, Leo E, Zhang H, Marchand C.DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010;17: 421–433.
  • Hayashi M, Unemoto T, Minami-Kakinuma S, Tanaka H, Omura S.The mode of action of nanaomycins D and A on a gram-negative marine bacterium Vibrio alginolyticus. J Antibiot 1982;35: 1078–1085.
  • Lu S, Tian J, Sun W et al.Bis-naphtho-gamma-pyrones from fungi and their bioactivities. Molecules 2014;19: 7169–7188.
  • Campbell JW, Cronan JEJr.Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu Rev Microbiol 2001;55: 305–332.
  • Williamson NR, Fineran PC, Gristwood T, Chawrai SR, Leeper FJ, Salmond GP.Anticancer and immunosuppressive properties of bacterial prodiginines. Future Microbiol 2007;2: 605–618.
  • Szybalski W, Iyer VN.Crosslinking of DNA by enzymatically or chemically activated mitomycins and porfiromycins, bifunctionally “alkylating” antibiotics. Fed Proc 1964;23: 946–957.
  • Tomasz M.Mitomycin C: small, fast and deadly (but very selective). Chem Biol 1995;2: 575–579.
  • Hollstein U.Actinomycin. Chemistry and mechanism of action. Chem Rev 1974;74: 625–652.
  • Sobell HM.Actinomycin and DNA transcription. Proc Natl Acad Sci USA 1985;82: 5328–5331.
  • Zhang Y.Persisters, persistent infections and the Yin-Yang model. Emerg Microb Infect 2014;3: e3.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.